The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
44 - I support a number of small products which are supported by one sales force. In order to simplify detailing efforts, I would like to produce one detail aid for all the products, with a few pages dedicated to each one. When it comes to the prescribing summaries, should these be placed together at the end of the detail aid, or with the pages related to that product?
-
Either option is fine. Another option would be to have loose-leaf prescribing information (PI) for each product that the representatives could distribute on request. The reps could offer the PI at the time of promotion of the detail aid. Code s7.3 says the PI "should form an integral part of the presentation or be attached to it". So it can be loose and accompany the piece. The doctor may choose only those PIs that he or she may want. We can save some trees.
